Research and Development
Established in 1999, we strongly value the importance of nurturing a working culture of innovation.
  • 20 % +
    of Revenue Invested in R&D
  • 30 %
    of Staff are R&D Professionals
  • 1,900 +
    Global Patent Applications have been Filed
    (As of 30 June 2023)
  • 13
    Leading or Participating in the Development of 13 Domestic and International Standards of Medical Devices
More
News
LifeTech News
LifeTech Scientific Corporation Announced 2023 Annual Results:International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid Development
LifeTech Scientific Corporation (the “Company” or “Lifetech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries announced the audited consolidated results for the year ended 31 December 2023.
2024 / 04 / 02
More Details
LifeTech News
LifeTech Scientific Corporation(1302.HK) Announces 2023 Interim Results
LifeTech Scientific Corporation (the “Company” or “Lifetech”), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced the unaudited consolidated results of the Company and its subsidiaries (collectively the “Group”) for the six months ended 30 June 2023 (the “Reporting Period”).
2023 / 08 / 30
More Details
LifeTech News
LifeTech Reports Steady Growth of 32.5percent in Net Profit Attributable to Owners of the Company in 2022
LifeTech Scientific Corporation (the “Company” or “Lifetech”), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced its 2022 annual results.
2023 / 03 / 30
More Details
LifeTech News
FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the US
LifeTech Scientific Corporation (Stock Code: 1302.HK) is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance coverage in the United States
2022 / 09 / 05
More Details
LifeTech News
LifeTech Scientific Corporation(1302.HK)Announces 2022 Interim Results
- Revenue increased by 20.4%, net profit attributable to owners of the Company increased by 34.4% after excluding certain non-recurring items
2022 / 08 / 31
More Details
Becoming a globally-recognized, trustworthy and innovative
interventional medical device enterprise
Contact Us